Your browser doesn't support javascript.
loading
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi, Alessandra; Carbognin, Luisa; Botticelli, Andrea; Paris, Ida; Fuso, Paolo; Savastano, Maria Cristina; La Verde, Nicla; Strina, Carla; Pedersini, Rebecca; Guarino, Stefania; Curigliano, Giuseppe; Criscitiello, Carmen; Raffaele, Mimma; Beano, Alessandra; Franco, Antonio; Valerio, Maria Rosaria; Verderame, Francesco; Fontana, Andrea; Haspinger, Eva Regina; Caldara, Alessia; Di Leone, Alba; Tortora, Giampaolo; Giannarelli, Diana; Scambia, Giovanni.
Afiliación
  • Fabi A; Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. alessandra.fabi@policlinicogemelli.it.
  • Carbognin L; Division of Gynecology Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Botticelli A; Medical Oncology Unit, La Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy.
  • Paris I; Division of Gynecology Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Fuso P; Division of Gynecology Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Savastano MC; Medical Oncology Unit, A.O.U. San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy.
  • La Verde N; Medical Oncology Unit, ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario, Milan, Italy.
  • Strina C; Medical Oncology Unit, Azienda Socio-Sanitaria Territoriale Cremona, Cremona, Italy.
  • Pedersini R; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
  • Guarino S; Medical Oncology Unit, Santa Maria della Misericordia Hospital, Urbino, Italy.
  • Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Criscitiello C; Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
  • Raffaele M; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Beano A; Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
  • Franco A; Dipartimento Oncologico, Presidio Cassia Sant'andrea, Asl Roma1, Rome, Italy.
  • Valerio MR; Department of Medical Oncology1, Città della Salute e della Scienza Hospital, Turin, Italy.
  • Verderame F; Breast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Fontana A; Medical Oncology, Policlinico Universitario P. Giaccone, Palermo, Italy.
  • Haspinger ER; Medical Oncology, AO Riuniti Villa Sofia, Cervello, Palermo, Italy.
  • Caldara A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Di Leone A; Azienda Sanitaria dell'Alto Adige - Ospedale di Merano, Merano, Italy.
  • Tortora G; Santa Chiara Hospital, Trento, Italy.
  • Giannarelli D; Breast Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Scambia G; Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
NPJ Breast Cancer ; 9(1): 89, 2023 Oct 30.
Article en En | MEDLINE | ID: mdl-37903774
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article País de afiliación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article País de afiliación: Italia